Study: Potential Cost Savings with Curing HCV

TargetHIV

"The cost of curing chronic HCV using DAAs [Direct Acting Antivirals to cure Hepatitis C, HCV] is now lower than a single year of disease burden in Medicaid." Thus reads the lead sentence in the Conclusion section of a December 2022 journal article, Impact of Direct-Acting Antiviral Use for Chronic Hepatitis C on Health Care Costs in Medicaid: Economic Model Update (American Journal of Managed Care) on a model examining the cost and savings that come with use of DAAs to cure HCV.

Access and timely treatment with HCV DAAs, however, remains complicated and restrictive under public and private health insurance programs. Calculating cost savings is a complex undertaking, according to Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens (Test, Evaluate, Monitor section in HCVGuidelines.org (AASLD/IDSA). 

Learn more about HCV services:

We'd like your feedback

Was this page helpful?
I found this page helpful because the content on the page:
Check all that apply
I did not find this page helpful because the content on the page:
Check all that apply
Please include an email address if you would like a response
Please include an email address if you would like a response
Did you use this approach in your work?
Not yet because
If no, why not?